uploads///Lyrica

How Did Pfizer’s Viagra and Lyrica Perform in 2017?

By

Updated

PFE’s Viagra revenue trends

In fiscal 2017, Pfizer’s (PFE) Viagra reported revenues of $1.2 billion, which represented a ~23% decline on a YoY (year-over-year) basis. In 2017, in the US and outside the US (international markets), Viagra generated revenues of $789 million and $416 million, respectively.

In 2017, in international markets, Viagra sales remained flat, compared with 2016 while, Viagra witnessed a 31% decline on a YoY basis in the US. In 4Q17, Viagra generated revenues of $209 million, which represents a ~45% rise on a YoY basis and a 32% rise on a quarter-over-quarter basis.

In 4Q17, in the US and in international markets, Viagra reported revenues of $102 million and $107 million, respectively, compared with $275 million and $106 million in 4Q16.

In the marketplace, Viagra faces stiff competition from Eli Lilly’s (LLY) Cialis, Bayer’s (BAYZF) Levitra, and Mist Pharmaceuticals’ Stendra.

Article continues below advertisement

Lyrica revenue trends

In fiscal 2017, Lyrica reported revenues of $5.1 billion, which reflected a ~2% rise on a YoY basis. In 2017, in the US and in international markets, Lyrica reported revenues of $3.4 billion and $1.6 billion, respectively, compared with $3.1 billion and $1.8 billion in 2016, reflecting ~10% growth and a ~12% decline, respectively, on a YoY basis.

In 4Q17, Lyrica reported revenues of $1.25 billion, which represents a ~2% rise on a YoY basis and 2% decline on a YoY basis. In 4Q17, in the US and in international markets, Lyrica reported revenues of $861 million and $393 million, respectively, compared with $782 million and $454 million in 4Q16.

Lyrica is used for the treatment of postherpetic neuralgia, partial-onset seizures, and fibromyalgia. Lyrica is also used for the treatment of neuropathic pain associated with diabetic peripheral neuropathy and spinal cord injury.

Some of Lyrica’s competitor drugs in the marketplace used for the treatment of fibromyalgia include Eli Lilly’s (LLY) Cymbalta and Allergan’s (AGN) Savella.

In the next part of this series, we’ll assess the performance of Pfizer’s inflammation and immunization portfolios in 4Q17 and 2017.

Advertisement

More From Market Realist